Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Deferred Revenue (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Current Deferred Revenue for 2 consecutive years, with $674000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Current Deferred Revenue fell 66.3% year-over-year to $674000.0, compared with a TTM value of $674000.0 through Mar 2023, down 66.3%, and an annual FY2022 reading of $1.3 million, changed N/A over the prior year.
  • Current Deferred Revenue was $674000.0 for Q1 2023 at Oramed Pharmaceuticals, down from $1.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.0 million in Q1 2022 and bottomed at $674000.0 in Q1 2023.